Related Experiment Video

Updated: Aug 30, 2026

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy

Virginia Wong1

  • 1Division of Neurodevelopmental Paediatrics, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, P.R. China. vcnwong@hkucc.hku.hk

Pediatric Rehabilitation
|October 10, 2003
PubMed

Insights

Botulinum toxin type A (BTX) effectively treats pes equinus in children with Cerebral Palsy (CP) by reducing muscle spasticity. Further research is needed to establish widespread recommendations for BTX use in CP management.

Area of Science:

  • Neurology
  • Pediatrics
  • Rehabilitation Medicine

Background:

  • Cerebral Palsy (CP) is a common childhood neurological disorder affecting movement and posture.
  • Spasticity, particularly in the gastrocnemius-soleus muscles causing pes equinus, is a significant challenge in CP management.
  • Botulinum toxin type A (BTX) is increasingly explored as an intervention for focal spasticity.

Purpose of the Study:

  • To systematically review the evidence on the efficacy of Botulinum toxin type A (BTX) for interventions in children with Cerebral Palsy (CP).
  • To evaluate the current evidence regarding BTX use for treating pes equinus secondary to gastrocnemius-soleus spasticity in pediatric CP patients.

Main Methods:

  • A systematic review employing the Sachett model of evidence-based medicine.
  • Analysis of existing literature on BTX interventions for spasticity in children with CP.

Main Results:

  • Current evidence indicates BTX is beneficial for treating pes equinus in children with CP.
  • Treatment success is contingent upon careful patient selection and clearly defined treatment goals.
  • BTX effectively targets spasticity in the gastrocnemius-soleus muscles.

Conclusions:

  • BTX shows promise as a treatment for specific types of spasticity in pediatric Cerebral Palsy.
  • Further multi-center clinical trials with standardized protocols are essential.
  • Widespread recommendations for BTX use in CP require more robust evidence.

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...